Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

A kind of synthetic method of telaprevir intermediate

A synthetic method, telaprevir technology, applied in the field of drug synthesis, can solve the problems of long reaction steps, unfavorable large-scale industrial production, and potential safety hazards, and achieve simple operation, avoid chiral racemization, and be suitable for large-scale The effect of industrial production

Inactive Publication Date: 2017-10-10
SUZHOU UUGENE BIOPHARMA
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0009] Although this synthesis method avoids the use of reagents such as cyclopropyl isonitrile, the reaction steps are long, requiring ten steps of reaction to obtain the final product, and the production cycle is long, resulting in high production costs, and the highly toxic cyanide is used in the synthesis method , there are potential safety hazards, which is not conducive to large-scale industrial production

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A kind of synthetic method of telaprevir intermediate
  • A kind of synthetic method of telaprevir intermediate
  • A kind of synthetic method of telaprevir intermediate

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0039]Add 100mL of formic acid to the three-necked reaction flask, add 10.5g of sodium percarbonate, 20g of ethyl butyryl acetate, and 1.3g of iodobenzene in sequence at 15-20°C. After the addition, continue to keep the internal temperature at 15-20°C for 2 hours. The complete conversion of the raw material was monitored by gas chromatography, the solvent formic acid was removed by concentration, and the residue was distilled under reduced pressure to obtain 19 g of intermediate B with a yield of 86.3%.

[0040] Make 13.75g of ammonium formate and 19g of intermediate B into a 100mL solution, adjust the pH of the solution to 8 with ammonia water, then add 0.3g of nicotinamide adenine dinucleotide (NAD) and 0.07g of dithiothreitol to obtain a mixed solution , adding the mixed solution into a 100mL solution containing 0.5g Pichia pastoris extract to form a reaction solution, the cell extract contains phenylalanine dehydrogenase and formate dehydrogenase by measuring; the reaction ...

Embodiment 2

[0043] Add 200mL of formic acid to the three-necked reaction flask, add 10.3g of sodium perborate, 39g of ethyl butyroacetate, and 2.2g of iodobenzene at 15-20°C. The complete conversion of raw materials was monitored by chromatography, the solvent formic acid was removed by concentration, and the residue was distilled under reduced pressure to obtain 27.3 g of intermediate B with a yield of 63.5%.

[0044] Make 19.8g of ammonium formate and 27.3g of intermediate B into a 150mL solution, adjust the pH of the solution to 8 with ammonia water, then add 0.44g of nicotinamide adenine dinucleotide (NAD) and 0.1g of dithiothreitol to obtain a mixture solution, the mixed solution was added into a 150mL solution containing 1.0g Pichia pastoris extract to form a reaction solution, and the cell extract contained phenylalanine dehydrogenase and formate dehydrogenase by measuring; Keep the temperature of the reaction solution at 35-40°C, stir at a speed of 80rpm, maintain the pH of the re...

Embodiment 3

[0047] Add 15mL of acetonitrile, 15mL of hydrogen peroxide, and 7g of sodium carbonate to the three-necked reaction flask in sequence. After stirring for 0.5 hours, continue to add 100mL of formic acid, 20g of ethyl butyryl acetate, and 1.3g of iodobenzene. After 2.5 hours, the complete conversion of the raw material was monitored by gas chromatography, the solvent formic acid was removed by concentration, and the residue was distilled under reduced pressure to obtain 8.5 g of intermediate B with a yield of 38.6%.

[0048] Prepare 6.15g of ammonium formate and 8.5g of intermediate B into a 50mL solution, adjust the pH of the solution to 8 with ammonia water, then add 0.13g of nicotinamide adenine dinucleotide (NAD) and 0.04g of dithiothreitol to obtain a mixture solution, the mixed solution was added into a 50mL solution containing 0.25g Pichia pastoris extract to form a reaction solution, and the cell extract contained phenylalanine dehydrogenase and formate dehydrogenase by m...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a synthesis method of telaprevir intermediate (S)-3-amino-N-cyclopropyl-2-hydroxyhexanamide hydrochloride, which belongs to the technical field of drug synthesis. The synthesis method comprises the following steps: successively adding formic acid to an oxidizing agent, raw material ethyl butyroacetate, and a catalyst, and reacting at 15-20° C. to obtain intermediate B; preparing ammonium formate and intermediate B into a solution, and then adding nicotinamide adenine Dinucleotide and dithiothreitol form a mixture, add the mixture to the solution of Pichia pastoris extract, react at 35-40°C and pH 8, then add di-tert-butyl dicarbonate Ester, react at 0-5°C to obtain intermediate C; heat cyclopropylamine and intermediate C to 65-75°C to complete the reaction, and post-process to obtain the final product; the structural formulas of intermediate B and intermediate C are as follows: the production cost of the present invention Low cost, environmental protection, simple operation, high product purity and yield, suitable for large-scale industrial production.

Description

technical field [0001] The invention relates to a synthesis method of a telaprevir intermediate, belonging to the technical field of drug synthesis. Background technique [0002] Telaprevir (telaprevir) is developed and marketed by Vertex Pharmaceutical Company. It is a new antiviral drug specific for hepatitis C. It is a reversible, selective, covalent, tight and slow binding of HCV NS3-4A protease Inhibitor, this protease is critical in viral replication. Telaprevir is approved for use in combination with pegylated interferon alfa and ribavirin for the treatment of patients who have not been treated with interferon-based anti-infective drugs, or who have not responded well to such treatments. The chemical name of telaprevir is (1S,3aR,6aS)-(2S)-2-Cyclohexyl-N-(pyrainylcarbonyl)glycyl-3-methyl-L-valyl-N-((1S)-1-(( cyclopropylamino)oxoacetyl)butyl)octahydrocyclopenta[c]pyrrole-1-carboxamide, CAS accession number: 402957-28-2, its chemical structural formula is: [0003] ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C12P13/02
Inventor 李志强王伸勇王晓俊胡长春
Owner SUZHOU UUGENE BIOPHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com